Rise and shine, everyone, another busy day is on the way. We can tell thanks to the never-ending parade of motor cars streaming outside our window and the joyous sounds of our official mascots, who are barking at passersby. As for us, we are immersed in the usual rituals, starting with heating the coffee kettle for another cup of stimulation. Today, our choice is vanilla cinnamon, for those tracking this sort of thing. Although we never mind drinking alone, you are invited to join us. Meanwhile, here is the latest menu of tidbits for you to peruse. We hope that your day is meaningful and productive, and that you will keep in touch when you hear something saucy. …
Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the case to insurers and governments to cover the cost of the effective but expensive drug, Reuters writes. The drugmaker presented the new long-term data on Tuesday at the European Congress on Obesity in Venice, Italy, in a new analysis from a large study for which substantial results had been published last year. The data could go some way to convince insurers and governments to reimburse Wegovy, which ranges from $200 to almost $2,000 a month in the 10 countries where it has been launched in so far.
An American woman who took part in the U.S. clinical trial for the AstraZeneca Covid-19 vaccine is suing the company, claiming it left her “permanently disabled,” The Telegraph writes. Her lawsuit is thought to be the first of its kind in the U.S., where the U.K-made vaccine was tested in clinical trials but never approved for use. Brianne Dressen, 42, a former teacher from Utah, says she developed a severe neurological condition after taking part in a vaccine trial in 2020. She is suing the company for an alleged breach of contract, after she said it failed to provide medical care for her side effects. More than 50 people have already filed a class action lawsuit against AstraZeneca in the U.K.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect